Section of Adult Congenital Heart Disease, Cardiovascular Diagnosis and Endoluminal Interventions, Rovigo General Hospital, Viale Tre Martiri, 45100 Rovigo, Italy.
J Geriatr Cardiol. 2012 Dec;9(4):389-400. doi: 10.3724/SP.J.1263.2012.05281.
During the last 20 years, the management of heart failure has significantly improved by means of new pharmacotherapies, more timely invasive treatments and device assisted therapies. Indeed, advances in mechanical support, namely with the development of more efficient left ventricular assist devices (LVADs), and the total artificial heart have reduced mortality and morbidity in patients awaiting transplantation, so much so, that LVADs are now approved of as a strategy for destination therapy. In this review, the authors describe in detail the current basic indications, functioning modalities, main limitations of surgical LAVDs, total artificial heart development, and percutaneous assist devices, trying to clarify this complex, but fascinating topic.
在过去的 20 年中，通过新的药物治疗、更及时的介入治疗和设备辅助治疗，心力衰竭的治疗得到了显著改善。事实上，机械支持的进步，尤其是更高效的左心室辅助装置（LVAD）和人工心脏的发展，降低了等待移植患者的死亡率和发病率，以至于 LVAD 现在被批准作为一种终末期治疗策略。在这篇综述中，作者详细描述了目前的基本适应证、LVAD 的工作方式、外科 LVAD 的主要局限性、人工心脏的发展和经皮辅助装置，试图阐明这个复杂但引人入胜的话题。
